Aquestive Therapeutics announced it will present multiple studies on its investigational oral epinephrine product, Anaphylm™ (dibutepinephrine) sublingual film, at the 2026 American College of Allergy, Asthma, and Immunology Annual Meeting. The presentations will cover pharmacokinetics, pharmacodynamics, and healthcare provider perspectives on epinephrine delivery for anaphylaxis treatment. Anaphylm is a small, easy-to-carry oral film designed to treat severe allergic reactions and is pending FDA approval. This product could become the first oral rescue medication for anaphylaxis if approved, representing a significant advancement in allergy treatment.
Aquestive Therapeutics is presenting data on its oral epinephrine product. For readers following the health sector, here is Pluang's market snapshot as of Nov 05, 2026 19:01 WIB: out of 150 priced US health stocks, 94 rose and 48 fell. Notable movers include Iovance Biotherapeutics Inc. (IOVA) at USD 9.20 with a +5.75% change, Alumis Inc. (ALMS) at USD 6.20 with a -5.34% change, and Oscar Health Inc. (OSCR) at USD 36.95 with a +5.00% change.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
